FDA Adds Blindness Warning to GLP-1 Drugs Like Ozempic, Zepbound

The significance here is less about the absolute risk — a handful of cases per 100,000 — than about labeling precedent for the fastest-growing drug class in years, which now carries an explicit vision-loss warning alongside its metabolic benefits. This touches prescribers and the large patient population already on or considering these therapies, and it hands plaintiff attorneys and payers a documented risk factor to cite. The open question is whether the warning shifts prescribing conversations or insurer coverage criteria, and whether reported NAION cases rise now that the label invites reporting.